Ann: Becoming a substantial holder from WAM, WAX, WMI, page-5

Good to see some discussion re SLA. The laser treatments are only around 31% of the business post ASC acquisition, with injectables the largest part of the business (& growing fast) at 37%. Other treatments are also popping up and becoming more popular, like skincare treatments and product, and other types of "body sculpting". In many respects, the basic laser treatment is the gateway to a whole variety of treatments that a customer may be interested in, in a world which as you say is increasingly superficial and open to cosmetic treatments. This also applies to males which, if I remember correctly, were approx. 5% of the customer base at the prospectus time; this could increase significantly over time with societal trends.. SLA seems well positioned to capitalise on these trends and is already profitable with a reasonable P/E and earnings growth .. (all IMHO only and DYOR)